Efficacy and Safety of Alprostadil Liposomes for Injection in the Treatment of Atherosclerotic Occlusive Disease of the Lower Extremities-A Phase II Multi-center Randomised Controlled Trial

NCT02877173 Phase 2 UNKNOWN

A phase II,randomized,double-blind,multi-doses,positive drug parallel controlled,multi-center clinical trial to evaluate initially the efficacy and safety of alprostadil liposomes for injection in the treatment of atherosclerotic occlusive disease of the lower extremities.

Details

Lead sponsor	Guangzhou Yipinhong Pharmaceutical CO.,LTD
Phase	Phase 2
Status	UNKNOWN
Enrolment	160
Start date	2016-08
Completion	2017-12

Conditions

• Arteriosclerosis Obliterans

Interventions

• Alprostadil Liposomes for Injection
• Alprostadil Injection

Primary outcomes

• Change from baseline in distance of asymptomatic disease and claudication after 3 weeks of treatment. — After 3 weeks of treatment
  Unit of distance of asymptomatic disease and claudication:meters

Countries

China